Analytical Data
-
Gene name
AURKA-INCENP Heterodimer
- Application
-
Alternative Names
AIK; ARK1; AURA; AURORA2; BTAK; STK15; STK6; STK7; Aurora/IPL1-related kinase 1; Breast tumor-amplified kinase; Serine/threonine-protein kinase 6
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14965
-
Expression Region
Met1~Val218
-
Molecular Weight
55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
AURKA (Aurora Kinase A) and INCENP (Inner Centromere Protein) are crucial components of the mitotic machinery, playing significant roles in cell division and maintaining genomic stability. The AURKA-INCENP heterodimer is essential for the proper functioning of the Aurora B kinase complex, which orchestrates various processes during mitosis, including chromosome alignment, segregation, and cytokinesis. Dysregulation of AURKA and INCENP is often implicated in tumorigenesis, making them targets for cancer therapy. Understanding the structural and functional dynamics of the AURKA-INCENP heterodimer is vital for elucidating the mechanisms underlying cell cycle regulation and the development of anticancer drugs. Recent advances in recombinant protein technology facilitate the expression and purification of this heterodimer, allowing for in-depth studies of its interactions, regulatory mechanisms, and pharmacological potential. Such research may pave the way for novel therapeutic strategies aimed at targeting the Aurora kinase pathway in various malignancies.
